Market Overview: Generic oncology sterile injectable are widely used for the treatment of cancers prostate, breast, colorectal, melanoma, lung, and bronchus. They have the same active ingredients as that of the branded version, with only the inactive contents of the drugs being different. Competitive Landscape: Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc. Key Market Drivers: Growing prevalence of chronic disease such as breast, prostate, colorectal, melanoma, lung, and bronchus is driving growth of the generic oncology sterile injectable market . According to the World Health Organization, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Increasing partnership and collaboration in the field of generic oncology sterile injectable is again fo...